Stephanie W Chang1, Daniel A Donoho2, Gabriel Zada3. 1. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 3. Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. gzada@usc.edu.
Abstract
INTRODUCTION: Differentiation of normal pituitary from abnormal tumor tissue remains a surgical challenge despite improvements in optical visualization technology for pituitary adenoma (PA) surgery. During neurosurgical procedures for other tumor types, 5-aminolevulinic acid (5-ALA) has become a focus of investigation based on its high specificity in differentiating tumor tissue. However, the role of 5-ALA and other optical fluorescent agents in PA surgery remains less clear. OBJECTIVE: To perform a systematic review on the use of various optical fluorescent agents in PA surgery. METHOD: Using PRISMA guidelines, a systematic literature review to identify reports describing 5-ALA and other optical agents for fluorescence-guided surgery for PA was performed. Eleven research studies met inclusion criteria and were reviewed. RESULTS: In two studies, 5-ALA was not shown to be effective in aiding PA resection using standard neurosurgical endoscopic/microscopic approaches. 5-ALA photodynamic therapy was evaluated in two in-vitro models with inconsistent results. Intraoperative use of indocyanine green (ICG) concluded with varying results, but showed a tendency towards improved differentiation of functional PA. OTL38 showed potential for intraoperative identification of nonfunctioning PA, particularly in tumors with high folate receptor expression. One study reported clinically useful fluorescence following sodium fluorescein administration. CONCLUSION: We conclude that selected optical fluorescent agents, including ICG and folate receptors, are most likely to hold promise for clinical use in differentiating PA from normal tissue.
INTRODUCTION: Differentiation of normal pituitary from abnormal tumor tissue remains a surgical challenge despite improvements in optical visualization technology for pituitary adenoma (PA) surgery. During neurosurgical procedures for other tumor types, 5-aminolevulinic acid (5-ALA) has become a focus of investigation based on its high specificity in differentiating tumor tissue. However, the role of 5-ALA and other optical fluorescent agents in PA surgery remains less clear. OBJECTIVE: To perform a systematic review on the use of various optical fluorescent agents in PA surgery. METHOD: Using PRISMA guidelines, a systematic literature review to identify reports describing 5-ALA and other optical agents for fluorescence-guided surgery for PA was performed. Eleven research studies met inclusion criteria and were reviewed. RESULTS: In two studies, 5-ALA was not shown to be effective in aiding PA resection using standard neurosurgical endoscopic/microscopic approaches. 5-ALA photodynamic therapy was evaluated in two in-vitro models with inconsistent results. Intraoperative use of indocyanine green (ICG) concluded with varying results, but showed a tendency towards improved differentiation of functional PA. OTL38 showed potential for intraoperative identification of nonfunctioning PA, particularly in tumors with high folate receptor expression. One study reported clinically useful fluorescence following sodium fluorescein administration. CONCLUSION: We conclude that selected optical fluorescent agents, including ICG and folate receptors, are most likely to hold promise for clinical use in differentiating PA from normal tissue.
Authors: Adrian F Daly; Martine Rixhon; Christelle Adam; Anastasia Dempegioti; Maria A Tichomirowa; Albert Beckers Journal: J Clin Endocrinol Metab Date: 2006-09-12 Impact factor: 5.958
Authors: B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro Journal: J Clin Endocrinol Metab Date: 2008-04-15 Impact factor: 5.958
Authors: John Robert Souter; Ignacio Jusue-Torres; Kurt Grahnke; Ewa Borys; Chirag Patel; Anand V Germanwala Journal: J Neurol Surg B Skull Base Date: 2019-11-11
Authors: Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis Journal: J Neurooncol Date: 2021-02-21 Impact factor: 4.130
Authors: Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639
Authors: Alexander Micko; Fabian Placzek; Roger Fonollà; Michael Winklehner; Ryan Sentosa; Arno Krause; Greisa Vila; Romana Höftberger; Marco Andreana; Wolfgang Drexler; Rainer A Leitgeb; Angelika Unterhuber; Stefan Wolfsberger Journal: Front Endocrinol (Lausanne) Date: 2021-10-18 Impact factor: 5.555
Authors: Rob A Vergeer; Mark R Postma; Jos M A Kuijlen; Gerrit van den Berg; Iris Schmidt; Astrid Gw Korsten-Meijer; Robert A Feijen; Schelto Kruijff; Wouter B Nagengast; J Marc C van Dijk; Wilfred F A den Dunnen; André P van Beek Journal: BMJ Open Date: 2021-10-07 Impact factor: 2.692
Authors: Elizaveta I Kozlikina; Kanamat T Efendiev; Andrey Yu Grigoriev; Olesia Y Bogdanova; Igor S Trifonov; Vladimir V Krylov; Victor B Loschenov Journal: Bioengineering (Basel) Date: 2022-01-28